HiCM-188 / Help Therap, China Resources Pharma - LARVOL DELTA

REVIVE-HEART: Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV) (clinicaltrials.gov) - P3 | N=80 | Not yet recruiting | Sponsor: Help Therapeutics

New P3 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease (clinicaltrials.gov) - P1/2 | N=16 | Not yet recruiting | Sponsor: Help Therapeutics

New P1/2 trial • Cardiovascular • Coronary Artery Disease • Heart Failure

Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure (clinicaltrials.gov) - P1/2 | N=36 | Active, not recruiting | Sponsor: Help Therapeutics | Trial completion date: Mar 2025 ➔ May 2027 | Trial primary completion date: Sep 2024 ➔ Nov 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Ischemic Heart Failure (ChiCTR) - P1/2 | N=36 | Completed | Sponsor: Chinese Academy of Medical Sciences Peking Union Medical College TEDA International Cardiovascular Hospital; Chinese Academy of Medical Sciences Pekin

New P1/2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

HEAL-CHF: Treating Heart Failure With hPSC-CMs (clinicaltrials.gov) - P1/2 | N=20 | Completed | Sponsor: Help Therapeutics | Recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

HELP Therapeutics and China Resources Sanjiu Announce Strategic Partnership to Co-Develop and Commercialize HiCM-188 for Advanced Heart Failure in Mainland China (PRNewswire) - "HELP Therapeutics, a global leader in regenerative medicine, and China Resources Sanjiu Pharmaceutical Company, one of China's largest pharmaceutical companies, have announced a strategic partnership to co-develop and commercialize the investigational cell therapy HiCM-188 in Mainland China."

Licensing / partnership • Cardiovascular

Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Help Therapeutics

New P1/2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

HEAL-CHF: Treating Heart Failure With hPSC-CMs (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Help Therapeutics | Trial completion date: May 2024 ➔ Oct 2024 | Trial primary completion date: Nov 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Treating Heart Failure With hiPSC-CMs (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Help Therapeutics | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Jul 2023 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

HEAL-CHF: Treating Heart Failure With hPSC-CMs (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Help Therapeutics | Trial completion date: Jul 2023 ➔ May 2024 | Trial primary completion date: Dec 2022 ➔ Nov 2023

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Help Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Help Therapeutics

New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

HEAL-CHF: Treating Heart Failure With hPSC-CMs (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Help Therapeutics | Trial completion date: Dec 2022 ➔ Jul 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Treating Heart Failure With hiPSC-CMs (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: Help Therapeutics | Initiation date: Jan 2022 ➔ Apr 2022

Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure

Treating Heart Failure With hiPSC-CMs (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: Help Therapeutics

New P1/2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Treating Congestive HF With hiPSC-CMs Through Endocardial Injection (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Help Therapeutics

New P1 trial • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • MRI